This spin-off from the Institute for Bioengineering of Catalonia has developed a non-invasive technology that analyses the metabolism of human embryos to select the most suitable ones for implantation. This innovation promises to significantly reduce the time and number of treatment cycles required for in vitro fertilisation. The success of LUMIRIS’ technology has led to a new round of investment of €1.5 million, bringing the total to €6 million since the company was founded in 2023.
LUMIRIS, an innovative spin-off from the Institute of Bioengineering of Catalonia (IBEC), has successfully closed a €1.5 million investment round, bringing its total funding to €6 million since its inception in 2023. The new capital injection will allow the company to enter the clinical phase next year, bringing it closer to its goal of bringing its revolutionary technology to market within three years to improve assisted reproduction treatments.
Thanks to the support of our investors, we are one step closer to fulfilling our mission to improve fertility treatment success rates and help millions of people on their journey to parenthood.
Anna Seriola
The company has developed a non-invasive imaging and diagnostic technology that can analyse the metabolism of human embryos, providing an accurate tool for identifying those most likely to implant in the uterus. This breakthrough will drastically reduce the waiting time for patients to become pregnant, thereby optimising the results of fertility treatments and minimising their emotional toll.
The recent investment round, which was partly funded by private investors and partly through the crowdfunding platform Capital Cell, reflects the market’s confidence in LUMIRIS’ disruptive technology and its potential to transform the assisted reproduction sector. In addition, the round was broadly supported by industry experts, further validating the company’s value proposition.
‘We are delighted to take this important step towards clinical validation of our technology. Thanks to the support of our investors, we are one step closer to fulfilling our mission to improve fertility treatment success rates and help millions of people on their journey to parenthood,’ said Dr Anna Seriola, co-founder and Chief Scientific Officer of LUMIRIS.
Thanks to this investment round, LUMIRIS has gained high visibility and awareness, which has allowed us to enter into important negotiations with leading pharmaceutical and photonics companies.
Samuel Ojosnegros
‘Thanks to this investment round, LUMIRIS has gained high visibility and awareness, which has allowed us to enter into important negotiations with leading pharmaceutical and photonics companies. This interest reinforces our confidence in the impact of our technology,’ adds Dr Samuel Ojosnegros, co-founder and CEO of LUMIRIS.
Since its creation, LUMIRIS has integrated the latest advances in photonics with a clear objective: to increase the success rate and reduce the time to pregnancy for people facing reproductive health challenges. With the support of prestigious assisted reproduction clinics, research centres and a multidisciplinary team, the company is positioning itself as an emerging reference in the field of biotechnology applied to fertility.
For more information about LUMIRIS and its innovative technology, please visit www.lumiris.tech.
LUMIRIS has received funding from the HYLIGHT project within the European Union's ATTRACT Phase 2 programme (project number 101004462).
